Lilly offers up to $3.8 billion for AtaiBeckley in bet on toad-derived ‘God molecule’

Summary

Eli Lilly has agreed to acquire AtaiBeckley for $2.8 billion upfront plus up to $1 billion in contingent payments, totaling up to $3.8 billion, marking the first major pharmaceutical company to develop a full program around a Schedule I psychedelic derived from toads.